Difference between revisions of "Niraparib (Zejula)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism per the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=615263 NCI Drug Dictionary]: An inhibitor of poly (ADP-ribo...") |
m |
||
| Line 1: | Line 1: | ||
| − | + | =General information= | |
| − | Class/mechanism per the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=615263 NCI Drug Dictionary]: An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. | + | Class/mechanism per the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=615263 NCI Drug Dictionary]: An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Niraparib inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway. The specific PARP family member target for niraparib is unknown. |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | ||
| − | = | + | =Diseases for which it is used= |
| − | + | *[[Ovarian cancer]] | |
| − | |||
| − | ==Also known as | + | =History of changes in FDA indication= |
| + | *3/27/2017: Initial FDA approval "for the maintenance treatment of adult patients with recurrent [[ovarian cancer|epithelial ovarian, fallopian tube, or primary peritoneal cancer]] who are in complete or partial response to [[:Category:Platinum_agents|platinum-based]] chemotherapy." | ||
| + | |||
| + | =Also known as= | ||
MK4827 | MK4827 | ||
| Line 22: | Line 24: | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| − | [[Category: | + | [[Category:Drugs FDA approved in 2017]] |
Revision as of 04:03, 28 March 2017
General information
Class/mechanism per the NCI Drug Dictionary: An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Niraparib inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway. The specific PARP family member target for niraparib is unknown.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Diseases for which it is used
History of changes in FDA indication
- 3/27/2017: Initial FDA approval "for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy."
Also known as
MK4827